These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 15552785)

  • 1. Value of FDG PET in the management of NSCLC.
    Ukena D; Hellwig D
    Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of FDG-PET in the management of non-small cell lung cancer.
    Stroobants S; Verschakelen J; Vansteenkiste J
    Eur J Radiol; 2003 Jan; 45(1):49-59. PubMed ID: 12499064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL; Fischman AJ
    Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration.
    Aquino SL; Asmuth JC; Alpert NM; Halpern EF; Fischman AJ
    J Comput Assist Tomogr; 2003; 27(4):479-84. PubMed ID: 12886128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET in staging lung cancer: how does it change the algorithm?
    Verhagen AF; Bootsma GP; Tjan-Heijnen VC; van der Wilt GJ; Cox AL; Brouwer MH; Corstens FH; Oyen WJ
    Lung Cancer; 2004 May; 44(2):175-81. PubMed ID: 15084382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.
    Truong MT; Viswanathan C; Erasmus JJ
    J Thorac Imaging; 2011 May; 26(2):132-46. PubMed ID: 21508735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis and reevaluation of lung cancer by positron emission tomography imaging.
    Erasmus JJ; Rohren E; Swisher SG
    Proc Am Thorac Soc; 2009 Apr; 6(2):171-9. PubMed ID: 19349485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of 18F-fluorodeoxyglucose positron emission tomography imaging in staging of non-small cell lung cancer].
    Guan Y; He S; Dong J
    Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1180-3. PubMed ID: 11769705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG PET: advantages for staging the mediastinum?
    Franzius C
    Lung Cancer; 2004 Aug; 45 Suppl 2():S69-74. PubMed ID: 15552784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of FDG-PET in the diagnosis and management of lung cancer.
    Oyen WJ; Bussink J; Verhagen AF; Corstens FH; Bootsma GP
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):561-7. PubMed ID: 15270660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology.
    Vansteenkiste JF; Stroobants SG
    Eur Respir J; 2001 Apr; 17(4):802-20. PubMed ID: 11401078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.
    Kim MP; Correa AM; Hofstetter W; Mehran R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Erasmus JJ; Swisher SG
    Ann Thorac Surg; 2015 Feb; 99(2):414-20. PubMed ID: 25497068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomography imaging in nonsmall-cell lung cancer.
    Erasmus JJ; Macapinlac HA; Swisher SG
    Cancer; 2007 Nov; 110(10):2155-68. PubMed ID: 17896784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of FDG-PET scanning in stage IIIAN2 non-small cell lung cancer].
    Colavolpe C; Bonardel G; Guedj E; Cammilleri S; Mundler O; Barlesi F
    Rev Mal Respir; 2012 Feb; 29(2):149-60. PubMed ID: 22405110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
    Heo EY; Yang SC; Yoo CG; Han SK; Shim YS; Kim YW
    Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
    Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
    Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging in lung cancer: positron emission tomography scan.
    Vansteenkiste JF
    Eur Respir J Suppl; 2002 Feb; 35():49s-60s. PubMed ID: 12064681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC).
    Miele E; Spinelli GP; Tomao F; Zullo A; De Marinis F; Pasciuti G; Rossi L; Zoratto F; Tomao S
    J Exp Clin Cancer Res; 2008 Oct; 27(1):52. PubMed ID: 18928537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of FDG-PET in the management of non-small cell lung carcinoma.
    Ho Shon IA; Maisey MN
    Ann Acad Med Singap; 2004 Mar; 33(2):166-74. PubMed ID: 15098629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to radiation.
    Rosenzweig KE; Fox JL; Giraud P
    Semin Radiat Oncol; 2004 Oct; 14(4):322-5. PubMed ID: 15558507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.